0001209191-23-011999.txt : 20230222
0001209191-23-011999.hdr.sgml : 20230222
20230222200437
ACCESSION NUMBER: 0001209191-23-011999
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230218
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Durgam Suresh K.
CENTRAL INDEX KEY: 0001829958
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 23655541
MAIL ADDRESS:
STREET 1: C/O INTER-CELLULAR THERAPIES, INC.
STREET 2: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-18
0
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001829958
Durgam Suresh K.
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
0
1
0
0
SVP, Chief Medical Officer
Common Stock
2023-02-18
4
M
0
8354
A
31458
D
Common Stock
2023-02-21
4
S
0
6673
46.55
D
24785
D
Common Stock
2023-02-21
4
S
0
800
47.20
D
23985
D
Common Stock
2023-02-21
4
S
0
806
48.63
D
23179
D
Common Stock
2023-02-21
4
S
0
75
49.60
D
23104
D
Restricted Stock Units
2023-02-18
4
M
0
8354
0.00
D
Common Stock
8354
0
D
Restricted stock units convert into common stock on a one-for-one basis.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this
sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.15 to $47.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.28 to $48.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On February 18, 2020, the reporting person was granted 25,062 restricted stock units, vesting in three equal annual installments beginning on
the first anniversary of the grant date.
/s/ Lawrence J. Hineline, Attorney-in-fact
2023-02-22